ADMA Biologics’ (ADMA) Buy Rating Reiterated at HC Wainwright

ADMA Biologics (NASDAQ:ADMA)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a note issued to investors on Monday, Benzinga reports. They currently have a $18.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 4.96% from the stock’s current price.

A number of other equities analysts have also weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price objective on shares of ADMA Biologics in a research report on Friday, September 20th. Mizuho increased their price target on shares of ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, June 20th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $15.50.

ADMA Biologics Trading Up 0.8 %

Shares of ADMA Biologics stock opened at $17.15 on Monday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87. The company has a market capitalization of $3.98 billion, a P/E ratio of -857.50 and a beta of 0.62. ADMA Biologics has a 1 year low of $3.06 and a 1 year high of $21.13. The company’s fifty day moving average is $17.72 and its two-hundred day moving average is $12.40.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The firm had revenue of $107.20 million for the quarter, compared to analysts’ expectations of $86.44 million. During the same quarter in the previous year, the firm posted ($0.02) EPS. The firm’s revenue for the quarter was up 78.4% on a year-over-year basis. Analysts forecast that ADMA Biologics will post 0.49 earnings per share for the current year.

Insider Buying and Selling

In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now owns 2,059,726 shares of the company’s stock, valued at approximately $36,436,552.94. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Lawrence P. Guiheen sold 9,000 shares of ADMA Biologics stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the transaction, the director now directly owns 153,941 shares in the company, valued at $2,843,290.27. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Adam S. Grossman sold 236,889 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the sale, the chief executive officer now directly owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 466,900 shares of company stock valued at $8,224,121. Corporate insiders own 3.70% of the company’s stock.

Institutional Trading of ADMA Biologics

Several institutional investors and hedge funds have recently made changes to their positions in ADMA. Mesirow Institutional Investment Management Inc. purchased a new stake in ADMA Biologics during the 1st quarter worth about $17,221,000. Bank of Montreal Can purchased a new stake in shares of ADMA Biologics during the second quarter worth about $17,886,000. D. E. Shaw & Co. Inc. raised its position in shares of ADMA Biologics by 26.8% in the second quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock valued at $76,298,000 after buying an additional 1,442,799 shares during the last quarter. Castleark Management LLC purchased a new position in shares of ADMA Biologics during the first quarter valued at approximately $5,400,000. Finally, Hillsdale Investment Management Inc. boosted its position in ADMA Biologics by 41,893.3% during the first quarter. Hillsdale Investment Management Inc. now owns 629,900 shares of the biotechnology company’s stock worth $4,157,000 after acquiring an additional 628,400 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.